Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects

This study has been terminated.
(Slow recruitment; trial unlikely to reach completion)
Information provided by:
GlaxoSmithKline Identifier:
First received: May 7, 2009
Last updated: March 31, 2011
Last verified: March 2011

The purpose of this study is to investigate the effect of drug A on its own and when it is given in combination with drug B on markers of brain activity. The study will

  1. Assess the effects of drug A and drug B on muscle movement after brain stimulation;
  2. Examine how the body handles (absorbs, distributes, breaks down and gets rid of) drug A and drug B when given in combination;
  3. Examine the safety of drug A and drug B when given together.

Condition Intervention Phase
Healthy Subjects
Healthy Volunteer
Bipolar Disorder
Drug: Placebo
Drug: Drug A (lamotrigine)
Drug: Drug B (vofopitant)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Double Blind, Double-dummy, Randomised, Placebo Controlled Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Effect of the study treatments on Resting Motor Thresholds (rMT) [ Time Frame: Within 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The safety and tolerability of the combination of study treatments. [ Time Frame: Within 24 hours ] [ Designated as safety issue: Yes ]

Enrollment: 12
Study Start Date: May 2009
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Placebo for both Drug A and Drug B
Experimental: Drug A (lamotrigine) Drug: Drug A (lamotrigine)
Experimental: Drug B (vofopitant) Drug: Drug B (vofopitant)


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subject
  • Male aged 18-65
  • Greater than 50kg weight
  • BMI 19-29.9 kg/m2

Exclusion Criteria:

  • Positive drug/alcohol screen
  • Positive HIV antibody
  • History of drug dependence
  • History of neurological disease
  • Pacemaker
  • Smoker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00907985

GSK Investigational Site
Goettingen, Niedersachsen, Germany, 37075
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT00907985     History of Changes
Other Study ID Numbers: 112676 
Study First Received: May 7, 2009
Last Updated: March 31, 2011
Health Authority: Germany: Bundesinstitut für Arzneimittel und Medizinprodukte

Keywords provided by GlaxoSmithKline:
Healthy Volunteer
Resting motor threshold (rMT)
Transcranial magnetic stimulation (TMS)

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neurokinin-1 Receptor Antagonists processed this record on September 29, 2016